Compare · HIMS vs REUN
HIMS vs REUN
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS carries a market cap of $4.11B.
- HIMS has hit the wire 24 times in the past 4 weeks while REUN has been quiet.
- HIMS has more recent analyst coverage (25 ratings vs 0 for REUN).
- Company
- Hims & Hers Health Inc.
- Reunion Neuroscience Inc.
- Price
- -
- -
- Market cap
- $4.11B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 0
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest HIMS
- Director Christopher D Payne converted options into 810 shares, increasing direct ownership by 2% to 35,673 units (SEC Form 4)
- Chief Legal Officer Soleil Boughton converted options into 42,262 shares and covered exercise/tax liability with 21,500 shares, increasing direct ownership by 7% to 314,648 units (SEC Form 4) (tax withholding)
- CTO Mohamed Elshenawy converted options into 188,286 shares and covered exercise/tax liability with 95,798 shares, increasing direct ownership by 50% to 278,044 units (SEC Form 4) (for withholding tax)
- Chief Medical Officer Patrick Harrison Carroll converted options into 25,927 shares and covered exercise/tax liability with 10,200 shares, increasing direct ownership by 8% to 213,574 units (SEC Form 4) (for tax liability)
- Chief Policy Officer Deborah M. Autor converted options into 39,974 shares and covered exercise/tax liability with 16,146 shares, increasing direct ownership by 49% to 72,789 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Michael Chi converted options into 69,769 shares and covered exercise/tax liability with 38,581 shares, increasing direct ownership by 7% to 487,848 units (SEC Form 4) (tax withholding)
- Director David B Wells converted options into 1,051 shares, increasing direct ownership by 0.46% to 230,859 units (SEC Form 4)
- Chief Financial Officer Oluyemi Okupe converted options into 71,616 shares and covered exercise/tax liability with 36,437 shares, increasing direct ownership by 15% to 269,706 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Andrew Dudum converted options into 154,990 shares and covered exercise/tax liability with 78,857 shares, increasing direct ownership by 7% to 1,109,310 units (SEC Form 4) to satisfy withholding obligation
- Director Payne Christopher D was granted 810 restricted stock units (SEC Form 4)
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement